Bjørn-Eivind Kirsebom, PhD, University Hospital of North Norway, Tromsø, Norway, discusses his work investigating the agreement between cerebrospinal fluid (CSF) and plasma p-tau biomarker positivity in patients with early Alzheimer’s disease. Having assessed p-tau217, p-tau181, and p-tau231, p-tau217 showed the strongest correlation between CSF and plasma levels in patients with preclinical and prodromal Alzheimer’s disease. Additionally, p-tau217 was the only marker associated with cognitive test performance overtime in cognitively normal individuals and those with mild cognitive impairment. By looking at biological severity based on CSF biomarkers, it was determined that p-tau217 had a more robust performance in the amyloid-positive tau-positive group than in the amyloid-positive tau-negative group. Dr Kirsebom comments on the implications of these findings for detecting very early disease cases in the clinic. This interview took place at the AP/PD 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
